Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates

About

We are creating a differentiated portfolio of potent, highly specific degraders, known as TRIMTACs^® and TRIMGLUEs^®, that selectively target the removal of toxic proteins for the treatment of intractable CNS and inflammatory disorders.

Learn more

Team

Led by a team of world-renowned scientists, experienced entrepreneurs and pharma and biotech executives with a proven track record of developing innovative technologies and novel therapeutics.

Learn more

Science

Our therapeutic approach is based on pioneering research into TRIM21, an underexploited but widely expressed ubiquitin ligase, that can be directed to treat protein aggregation disorders and bring therapeutic benefits.

Learn more

Latest News

TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board 02 December 2025
TRIMTECH Therapeutics appoints Dr Mike Hutton to Scientific Advisory Board 11 November 2025

All news

Events

Accelerating Bio-Innovation
20 – 22 April 2026
Cambridge, UK
Anglonordic Life Science Conference XXII
23 April 2026
London, UK

All events